Serological testing for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies may play a critical role in the management of the worldwide health crisis. Such testing may reveal key information for epidemiology, convalescent plasma therapies and vaccine development. However, the situation is complex, and much is unknown. Although such testing may ultimately be used to…
Prescribing stewardship is just one ethical consideration facing rheumatologists during the COVID-19 pandemic.
The FDA has approved a 25 mg/mL dose of an oral solution of celecoxib to treat adults with acute migraine…
Although the COVID-19 outbreak has shifted the focus and approach of advocacy efforts, ACR staff and the Government Affairs Committee continue to work on behalf of rheumatology providers and patients.
Despite efforts by the ACR and other organizations, Blue Cross Blue Shield of Tennessee has indicated that it will move forward with implementation of its specialty pharmacy acquisition mandate on July 1, 2020.
NEW YORK, June 4 (Reuters)—Three of the authors of an influential article that found hydroxychloroquine (HCQ) increased the risk of death in COVID-19 patients retracted the study, citing concerns about the quality of the data behind it. The anti-malarial drug has been controversial in part due to support from U.S. President Donald Trump, as well…
The FDA is reviewing supplemental Biologics License Applications for golimumab to treat polyarticular JIA and juvenile PsA…
NEW YORK (Reuters Health)—Long-term rituximab use lowers the chance of relapse of anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis (AAV), compared with standard maintenance therapy, according to a report from the MAINRITSAN3 randomized trial. “Physicians should consider AAV to be a long-lasting, chronic disease which requires maintenance therapy,” says Dr. Pierre Charles of Cochin Hospital, Paris…
Recent research found women with COPD and asthma—even those who have never smoked—are at a higher risk of developing rheumatoid arthritis…
CHICAGO (Reuters)—Cancer patients with COVID-19 who were treated with a drug combination promoted by U.S. President Donald Trump to counter the coronavirus were three times more likely to die within 30 days than those who got either drug alone, U.S. researchers reported on May 28. The preliminary results suggest doctors may want to refrain from…